Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a biopharmaceutical company focused on infectious disease and dermatology, today announced that data received from the National Cancer Institute ("NCI") showed that two of Ceragenix's Ceragenin(TM) compounds inhibit angiogenesis at low micromolar concentrations.
